Rockefeller Philanthropy Advisors helps donors create thoughtful, effective philanthropy throughout the world. RPA assists individuals, trusts, foundations and corporations in achieving their philanthropy goals and acts as a fiscal sponsor for innovative nonprofit initiatives and funder collaboratives.
Established in 1992 in DE
COVID-19 Early Treatment Fund (CETF)
COVID-19 Early Treatment Fund (CETF) was established by entrepreneur and philanthropist Steve Kirsch to fund outpatient clinical trials on re-purposed drugs, the quickest, safest, and lowest cost way to re-open our world until better drugs are discovered. CETF is managed by Rockefeller Philanthropy Advisors (RPA), a 501(c)(3) charity. The CETF Scientific Advisory Board (SAB) recommends the grants and RPA disburses the funds. The scientific advisory board includes Dr. Robert Siliciano, an immunologist and virologist Johns Hopkins University; Dr. Rich D’Aquila, an infectious disease expert at Northwestern University and Harvard clinical trials expert Dr. Raj Gandhi.
New applications are not currently being reviewed. Applicants may fill out the online form and the foundation will respond once it begins reviewing applications.